Search

Your search keyword '"Mouroux J"' showing total 405 results
Start Over Author "Mouroux J"
405 results on '"Mouroux J"'

9. Multicentre study of neoadjuvant chemotherapy for stage I and II oesophageal cancer

Author

Bekkar, S., Gronnier, C., Renaud, F., Duhamel, A., Pasquer, A., Théreaux, J., Gagnière, J., Meunier, B., Collet, D., Mariette, C., Dhahri, A., Lignier, D., Cossé, C., Regimbeau, J.-M., Luc, G., Cabau, M., Jougon, J., Badic, B., Lozach, P., Bail, J. P., Cappeliez, S., El Nakadi, I., Lebreton, G., Alves, A., Flamein, R., Pezet, D., Pipitone, F., Stan-Iuga, B., Contival, N., Pappalardo, E., Coueffe, X., Msika, S., Mantziari, S., Demartines, N., Hec, F., Vanderbeken, M., Tessier, W., Briez, N., Fredon, F., Gainant, A., Mathonnet, M., Bigourdan, J. M., Mezoughi, S., Ducerf, C., Baulieux, J., Mabrut, J.-Y., Baraket, O., Poncet, G., Adam, M., Vaudoyer, D., Enfer, P. Jourdan, Villeneuve, L., Glehen, O., Coste, T., Fabre, J.-M., Marchal, F., Frisoni, R., Ayav, A., Brunaud, L., Bresler, L., Cohen, C., Aze, O., Venissac, N., Pop, D., Mouroux, J., Donici, I., Prudhomme, M., Felli, E., Lisunfui, S., Seman, M., Petit, G. Godiris, Karoui, M., Tresallet, C., Ménégaux, F., Vaillant, J.-C., Hannoun, L., Malgras, B., Lantuas, D., Pautrat, K., Pocard, M., Valleur, P., Lefevre, J. H., Chafai, N., Balladur, P., Lefrançois, M., Parc, Y., Paye, F., Tiret, E., Nedelcu, M., Laface, L., Perniceni, T., Gayet, B., Turner, K., Filipello, A., Porcheron, J., Tiffet, O., Kamlet, N., Chemaly, R., Klipfel, A., Pessaux, P., Brigand, C., Rohr, S., Carrère, N., Da Re, C., Dumont, F., Goéré, D., Elias, D., and Bertrand, C.

Published
2016
Full Text
View/download PDF

15. Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method

Author

Hofman, V., Long, E., Ilie, M., Bonnetaud, C., Vignaud, J. M., Fléjou, J. F., Lantuejoul, S., Piaton, E., Mourad, N., Butori, C., Selva, E., Marquette, C. H., Poudenx, M., Sibon, S., Kelhef, S., Vénissac, N., Jais, J. P., Mouroux, J., Molina, T. J., Vielh, P., and Hofman, P.

Published
2012
Full Text
View/download PDF

27. Impact of Neoadjuvant Chemoradiotherapy on Postoperative Outcomes After Esophageal Cancer Resection

Author

Gronnier, Caroline, Tréchot, Boris, Duhamel, Alain, Mabrut, Jean-Yves, Bail, Jean-Pierre, Carrère, Nicolas, Lefevre, Jérémie, Brigand, Cécile, Vaillant, Christophe, Adham, Mustapha, Msika, Simon, Demartines, Nicolas, El Nakadi, Issam, Piessen, Guillaume, Meunier, B., Collet, Denis, Mariette, Christophe, Luc, G., Cabau, Magalie, Jougon, Jacques, Badic, Bogdan, Lozach, Patrick, Cappeliez, Serge, Lebreton, G., Alves, A., Flamein, Renaud, Pezet, Denis, Pipitone, Federica, Contival, Nicolas, Pappalardo, Eric, Mantziari, Styliani, Hec, F., Vanderbeken, Marguerite, Tessier, Williams, Briez, Nicolas, Fredon, F, Gainant, Alain, Mathonnet, Muriel, Bigourdan, Jm, Mezoughi, Salim, Ducerf, C., Baulieux, Jacques, Pasquer, Arnaud, Baraket, Oussama, Poncet, Gilles, Vaudoyer, Delphine, Enfer, J, Villeneuve, L, Glehen, O., Coste, T, Fabre, J.M, Marchal, F, Frisoni, Romain, Ayav, Ahmet, Brunaud, Laurent, Bresler, Laurent, Cohen, C, Aze, Olivier, Vénissac, Nicolas, Pop, D., Mouroux, J, Donici, Ion, Prudhomme, M., Felli, E., Lisunfui, Stéphanie, Seman, Marie, Petit, Gaelle Godiris, Karoui, M, Tresallet, Christophe, Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, Service d'Hématologie [CHU Huriez Lille], Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille, Université Lille Nord de France (COMUE), Site de Recherche Intégrée en Cancérologie (SIRIC-ONCOLille), Université de Lille, Sciences et Technologies-Université de Lille, Sciences Humaines et Sociales-Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER-Université Lille Nord de France (COMUE)-UNICANCER-Cancéropole Nord-Ouest-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de biostatistiques [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département de chirurgie digestive, Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital de Hautepierre [Strasbourg], CHU Pitié-Salpêtrière [AP-HP], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), CHU Pontchaillou [Rennes], Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], CIC-IT Bordeaux, Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service de chirurgie générale et viscérale, Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), CHU Clermont-Ferrand, Service Chirurgie Digestive, Service de Chirurgie Générale et Digestive[Lille], Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Chirurgie digestive, endocrinienne et générale [CHU Limoges], CHU Limoges, Homéostasie Cellulaire et Pathologies (HCP), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Alimentary Tract Surgery, University Hospital, Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Institut Charles Gerhardt Montpellier - Institut de Chimie Moléculaire et des Matériaux de Montpellier (ICGM ICMMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Institut de Chimie du CNRS (INC), Service de Chirurgie Digestive Hépatobiliaire et Endocrine [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Department of Thoracic Surgery, Louis Pasteur Hospital, Service de Chirurgie Générale, Viscérale et Endocrinienne [CHU Pitié-Sapêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Université de Lille-UNICANCER-Université de Lille-UNICANCER-Cancéropole Nord-Ouest-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Biostatistiques [CHRU Lille], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Sciences et Technologies - Bordeaux 1 (UB)-CHU Bordeaux [Bordeaux], and Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience; Objectives: To assess the impact of neoadjuvant chemoradiotherapy (NCRT) on anastomotic leakage (AL) and other postoperative outcomes after esophageal cancer (EC) resection.Background: Conflicting data have emerged from randomized studies regarding the impact of NCRT on AL.Methods: Among 2944 consecutive patients operated on for EC between 2000 and 2010 in 30 European centers, patients treated by NCRT after surgery (n = 593) were compared with those treated by primary surgery (n = 1487). Multivariable analyses and propensity score matching were used to compensate for the differences in some baseline characteristics.Results: Patients in the NCRT group were younger, with a higher prevalence of male sex, malnutrition, advanced tumor stage, squamous cell carcinoma, and surgery after 2005 when compared with the primary surgery group. Postoperative AL rates were 8.8% versus 10.6% (P = 0.220), and 90-day postoperative mortality and morbidity rates were 9.3% versus 7.2% (P = 0.110) and 33.4% versus 32.1% (P = 0.564), respectively. Pulmonary complication rates did not differ between groups (24.6% vs 22.5%; P = 0.291), whereas chylothorax (2.5% vs 1.2%; P = 0.020), cardiovascular complications (8.6% vs 0.1%; P = 0.037), and thromboembolic events (8.6% vs 6.0%; P = 0.037) were higher in the NCRT group. After propensity score matching, AL rates were 8.8% versus 11.3% (P = 0.228), with more chylothorax (2.5% vs 0.7%; P = 0.030) and trend toward more cardiovascular and thromboembolic events in the NCRT group (P = 0.069). Predictors of AL were high American Society of Anesthesiologists scores, supracarinal tumoral location, and cervical anastomosis, but not NCRT.Conclusions: Neoadjuvant chemoradiotherapy does not have an impact on the AL rate after EC resection (NCT 01927016).

Published
2014

28. Adénocarcinome sur endobrachyœsophage. Étude de 28 cas réséqués

Author

A. Myx, Bourgeon A, Bernard Jl, Mouroux J, P. Baque, Richelme H, and Benchimol D

Subjects
Gynecology, medicine.medical_specialty, Endobrachyesophagus, High grade dysplasia, business.industry, Neoplasm Invasiveness, medicine, Follow up studies, Esophageal adenocarcinoma, Surgery, Neoplasm staging, business, Premalignant lesion
Abstract

Resume Objectif de l'etude L'objectif de cette etude retrospective est de rapporter une serie de 28 malades traites par resection œsophagienne pour un adenocarcinome sur endobrachyœsophage (EBO). Patients et methodes De 1992 a 1998, 28 patients ont ete operes pour un adenocarcinome sur endobrachyœsophage. Il s'agissait de 27 hommes et d'une femme âges en moyenne de 65 ans, classes ASA I (n = 2), ASA II (n = 15), ASA III (n = 11). Dix-huit patients avaient des antecedents de reflux gastro-œsophagien ayant motive une operation antireflux chez cinq d'entre eux. La dysphagie a ete le signe revelateur le plus frequent (n = 19). L'œsophagectomie a ete realisee par la technique de Santy-Lewis dans 15 cas, sans thoracotomie dans neuf cas et par voie thoracique gauche dans quatre cas. Resultats L'examen anatomopathologique de la piece operatoire a montre qu'il s'agissait 27 fois d'un adenocarcinome et une fois d'une dysplasie severe. Cinq patients avaient un EBO connu et parmi eux, les trois qui etaient soumis a une surveillance endoscopique avaient une dysplasie severe et une tumeur classee T1 (n = 2), alors que les deux autres non surveilles avaient une tumeur classee T3N1. Il y a eu trois deces postoperatoires (mortalite: 10 %) tous d'origine respiratoire. Les autres ont pu retrouver une alimentation normale. La survie mediane a ete de 16,6 mois ; 14 patients sont decedes, sept de leur cancer, sept d'une cause intercurrente. La survie actuarielle a ete de 63 % a un an, 42 % a deux ans et 15, 2 % a quatre ans. Une analyse multifactorielle a permis d'identifier trois facteurs de pronostic: le score ASA, l'existence d'un EBO connu et suivi et la longueur de l'EBO. Conclusion L'adenocarcinome sur EBO est trop souvent decele a un stade avance. Les patients a risque necessitent une surveillance endoscopique. Une dysplasie de haut grade decouverte a deux examens successifs par deux anatomopathologistes independants peut conduire a une resection œsophagienne prophylactique mais les traitements locaux par voie endoscopique qui sont en cours d'evaluation pourraient permettre de l'eviter dans l'avenir.

Published
1999

30. Impact of Kras mutant subtypes on PD-L1 expression in lung adenocarcinoma

Author

Falk, A.T., primary, Yazbeck, N., additional, Thon, L., additional, Guibert, N., additional, Hofman, V., additional, Zahaf, K., additional, Lespinet, V., additional, Bordone, O., additional, Tanga, V., additional, Washetine, K., additional, Cohen, C., additional, Venissac, N., additional, Mouroux, J., additional, Marquette, C.-H., additional, Brest, P., additional, Ilié, M., additional, and Hofman, P., additional

Published
2016
Full Text
View/download PDF

36. External validation of a risk score in the prediction of the mortality after esophagectomy for cancer.

Author

D'Journo, X. B., Berbis, J., Jougon, J., Brichon, P.-Y., Mouroux, J., Tiffet, O., Bernard, A., de Dominicis, F., Massard, G., Falcoz, P. E., Thomas, P., and Dahan, M.

Subjects
ESOPHAGECTOMY, TREATMENT of esophageal cancer, DEATH rate, COMORBIDITY, SURGICAL complications
Abstract

This study was designed as an external evaluation of the Steyerberg score in the prediction of different categories of postoperative mortality after esophagectomy on a large nationwide database of thoracic surgeons. Data collection was obtained from the Epithor national database encompassing the majority of thoracic procedures performed in France. We retrospectively compared the predicted to the observed postoperative 30-day (30DM), 90-day (90DM) and in-hospital mortality (IHM) rate in each decile of equal patient. Patients included in the study were operated for an esophageal cancer and Gastroesophageal junction (GEJ). Steyerberg score was determined according to its logarithmic formula obtained from a sum score including age, comorbidities, neoadjuvant treatment and hospital volume. Deviation of observed from theoretically expected number of deaths was investigated using the calibration test of Hosmer-Lemeshow. Discrimination of the score was determined using the measure of the area under the receiver operating characteristic curve (AUC) of each category of mortality. Over a 9-year period, 1039 consecutive patients underwent an esophagectomy over 42 centers. Among them, 18 centers were considered as intermediate or high-volume institutions, and 24 were low-volume institutions. There were 841 males (81%) with a mean age of 62.3 ± 10 years. Preoperative treatment was allocated to 420 patients (40%). Numbers of comorbidity was: 1 in 261 patients (25%), 2 in 264 patients (25%), 3 in 383 patients (36%) and 4 in 5 patients (1%). The 30DM, 90DM and IHM rate were, respectively, 5.6%, 9.2% and 9.6%. The main causes of postoperative deaths were related to pulmonary complications (44%), complications of the gastric interposition (28%), cardiologic and thromboembolism events (10%). For 30DM, there were significant differences between predicted/observed mortalities in four deciles, whereas there was no significant difference for 90DM and for IHM. In term of calibration, there was a fair agreement of the Steyerberg score with observed 30DM. Predictions were above 20% for seven deciles. Calibration seemed more adequate for 90DM and for IHM. Predictions were above 20% for only three deciles but deviations were not significant. In terms of discrimination, for the 30DM the Steyerberg score overpredicted, the observed mortality rate and AUC was 0.64 (CI 95%: 0.57-0.71). For the 90DM, AUC indicated 0.63 (CI 95%: 0.57-0.68). For the IHM, AUC indicated 0.63 (CI 95%: 0.58-0.68). Steyerberg scoring system seems to be a moderate risk score of the prediction of the IHM and 90DM. This score appears to have a fair discrimination for the 30DM. Nevertheless, because of its simplicity, we believe that this simple predictive score is relevant and transportable to others institution performing such surgery for benchmarking purposes. A reappraisal of the score adapted to current surgical cohort is required. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

38. Detection of Circulating Tumor Cells from Lung Cancer Patients in the Era of Targeted Therapy : Promises, Drawbacks and Pitfalls

Author

Hofman, V., primary, Ilie, M., additional, Long, E., additional, Guibert, N., additional, Selva, E., additional, Washetine, K., additional, Mograbi, B., additional, Mouroux, J., additional, Venissac, N., additional, Reverso-Meinietti, J., additional, Milano, G., additional, Mazieres, J., additional, Marquette, C.-H., additional, Paterlini-Brechot, P., additional, and Hofman, P., additional

Published
2014
Full Text
View/download PDF

40. Analyse corrélative du statut mutationnel du gène KRAS sur l’ADN libre plasmatique et les tumeurs primitives dans une série de 65 adénocarcinomes bronchiques. Approche « ciblée » versus approche à « haut débit »

Author

Guibert, N., primary, Ilie, M., additional, Hofman, V., additional, Bordone, O., additional, Selva, E., additional, Boyer, J., additional, Lespinet, V., additional, Mollet, C., additional, Ebran, N., additional, Milano, G., additional, Vénissac, N., additional, Mouroux, J., additional, Poudenx, M., additional, Mazières, J., additional, Hugo Marquette, C., additional, and Hofman, P., additional

Published
2014
Full Text
View/download PDF

41. Sécrétion extra-gestationnelle de ßHCG révélatrice d’un carcinome trophoblastique épithélioïde pulmonaire primitif : l’analyse des polymorphismes génétiques permet d’incriminer le transfert maternel de cellules fœtoplacentaires 4ans auparavant

Author

Fénichel, P., primary, Butori, C., additional, Rouzier, C., additional, Chevallier, P., additional, Thyss, A., additional, Poullot, A.G., additional, Paul, C., additional, Panaïa-Ferrari, P., additional, and Mouroux, J., additional

Published
2013
Full Text
View/download PDF

43. Réponse dynamique des anhydrases carboniques IX et XII pendant la réoxygénation tumorale : impact sur l’agressivité tumorale et la dualité pronostique chez les patients atteints d’un carcinome pulmonaire non à petite cellules (CPNPC)

Author

Ilie, M., primary, Hofman, V., additional, Butori, C., additional, Bonnetaud, C., additional, Mouroux, J., additional, Mazure, N.-M., additional, Pouysségur, J., additional, Brest, P., additional, and Hofman, P., additional

Published
2012
Full Text
View/download PDF

44. Le réarrangement du gène EML4-ALK : analyse comparative sur les cellules tumorales circulantes et le tissu tumoral à partir de 87 cas d’adénocarcinomes pulmonaires

Author

Ilie, M., primary, Long, E., additional, Butori, C., additional, Hofman, V., additional, Coelle, C., additional, Mauro, V., additional, Zahaf, K., additional, Marquette, C.-H., additional, Mouroux, J., additional, Paterlini-Bréchot, P., additional, and Hofman, P., additional

Published
2012
Full Text
View/download PDF

45. Intérêt d’une collaboration entre les tumorothèques et les modèles animaux : taux élevé de prise des xénogreffes issues de carcinomes non à petites cellules humains dans un circuit complexe

Author

Ilie, M., primary, Blot, L., additional, Hofman, V., additional, Long, E., additional, Nunes, M., additional, Butori, C., additional, Selva, E., additional, Merino-Trigo, A., additional, Vénissac, N., additional, Mouroux, J., additional, Vrignaud, P., additional, and Hofman, P., additional

Published
2012
Full Text
View/download PDF

46. Analyse du statut mutationnel du gène KRAS à partir de 442 adénocarcinomes bronchopulmonaires d’une population française caucasienne : corrélation avec le statut tabagique, les sous-types histologiques, le stade pTNM et l’évolution clinique

Author

Hofman, V., primary, Ilie, M., additional, Long, E., additional, Butori, C., additional, Lespinet, V., additional, Bordone, O., additional, Bonnetaud, C., additional, Marquette, C.-H., additional, Vénissac, N., additional, Mouroux, J., additional, and Hofman, P., additional

Published
2012
Full Text
View/download PDF

50. Cisplatin-Docetaxel Induction plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer Patients: A Phase II Trial

Author

Poudenx, M., primary, Bondiau, P.Y., additional, Chamorey, E., additional, Venissac, N., additional, Otto, J., additional, Pourel, N., additional, Castelnau, O., additional, Tessier, E., additional, De Surmont Salasc, B., additional, Berdah, J.F., additional, Pop, D., additional, Michel, C., additional, and Mouroux, J., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results